Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FHCZ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $19,318.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Nucala 100 mg/mL auto-injector medication. The award, issued on January 2, 2026, with an ultimate completion date of January 5, 2026, carries firm fixed-price terms and was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition vehicle established to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's comprehensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables spanning multiple therapeutic categories. The PPV-G GEN V contract, awarded on November 13, 2025, and extending through December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors under the broader $30.3 billion acquisition strategy, enabling the company to fulfill diverse and specialized pharmaceutical requirements for Department of Defense global healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHCZ1?
SPE2DR26FHCZ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FHCZ1 worth?
The government has obligated $19,318 on SPE2DR26FHCZ1.
Is contract SPE2DR26FHCZ1 an order under another contract?
Yes. SPE2DR26FHCZ1 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCZ1 competed?
The extent of competition for SPE2DR26FHCZ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award